Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery
NCT ID: NCT01841450
Last Updated: 2021-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
360 participants
INTERVENTIONAL
2013-07-31
2021-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
iStent
Implantation of one iStent in conjunction with cataract surgery
iStent
Implantation of one iStent in conjunction with cataract surgery
Cataract surgery
Cataract surgery alone
Cataract surgery
Cataract surgery alone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
iStent
Implantation of one iStent in conjunction with cataract surgery
Cataract surgery
Cataract surgery alone
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* currently treated with ocular hypotensive medication
* pseudoexfoliative and pigmentary glaucoma are acceptable diagnoses
* subject scheduled to undergo cataract surgery
Exclusion Criteria
* retrobulbar tumor, thyroid eye disease, Sturge-Weber syndrome or any other type of condition that may cause elevated episcleral venous pressure
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glaukos Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Irvine, California, United States
Montebello, California, United States
Aurora, Colorado, United States
Atlanta, Georgia, United States
Edgewood, Kentucky, United States
Louisville, Kentucky, United States
Jackson, Michigan, United States
Saint Joseph, Michigan, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Mentor, Ohio, United States
Kingston, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GTS100-PAS2 (Rev1 04-11-2016)
Identifier Type: -
Identifier Source: org_study_id